Onco-Innovations Limited (CSE:ONCO)(Frankfurt:W1H ,WKN:A3EKSZ) ("Onco" or the "Company") is pleased to provide information on its exclusive-licensed technology, a new class of Polynucleotide ...

Onco-Innovations Limited (CSE:ONCO)(Frankfurt:W1H ,WKN:A3EKSZ) ("Onco" or the "Company") is pleased to provide information on its exclusive-licensed technology, a new class of Polynucleotide ...

Onco-Innovations Limited (CSE:ONCO)(Frankfurt:W1H ,WKN:A3EKSZ) ("Onco" or the "Company") is pleased to provide information on its exclusive-licensed technology, a new class of Polynucleotide Kinase 3' ...

Cincinnati, OH, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ: ONCO) (the “Company”) announced that it received a letter from The Nasdaq Capital Market (“Nasdaq”) on December 6, 2024 ...

At that time, pharmaphorum spoke with Dr Simon Holt, surgical oncologist at NHS Wales, discussing the state of breast cancer care in the UK and how products like Oncotype DX can actually save the ...

VANCOUVER, BC / ACCESS Newswire / February 10, 2025 / Onco-Innovations Limited (CSE:ONCO)(Frankfurt:W1H ,WKN:A3EKSZ) ("Onco" or the "Company") is pleased to provide information on its ...

VANCOUVER, BC / ACCESS Newswire / February 6, 2025 / Onco-Innovations Limited (CSE:ONCO)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco" or the "Company") is pleased to announce that its wholly-owned subsidiary, ...

VANCOUVER, BC / ACCESS Newswire / February 10, 2025 / Onco-Innovations Limited (CSE:ONCO)(Frankfurt:W1H ,WKN:A3EKSZ) ('Onco' or the 'Company') is pleased to provide information on its ...

Onco-Innovations' Licensed PNKP Inhibitor Technology Shown to Increase Sensitivity of Cancer Cells to Radiation in Animal Study ACCESS Newswire Feb 10, 2025 ...

VANCOUVER, BC / ACCESS Newswire / February 6, 2025 / Onco-Innovations Limited (CSE:ONCO)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco" or the "Company") is pleased to announce that its wholly-owned ...